Literature DB >> 13679574

Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Mounia Azzi1, Pascale G Charest, Stéphane Angers, Guy Rousseau, Trudy Kohout, Michel Bouvier, Graciela Piñeyro.   

Abstract

It is becoming increasingly clear that signaling via G protein-coupled receptors is a diverse phenomenon involving receptor interaction with a variety of signaling partners. Despite this diversity, receptor ligands are commonly classified only according to their ability to modify G protein-dependent signaling. Here we show that beta2AR ligands like ICI118551 and propranolol, which are inverse agonists for Gs-stimulated adenylyl cyclase, induce partial agonist responses for the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) 1/2 thus behaving as dual efficacy ligands. ERK1/2 activation by dual efficacy ligands was not affected by ADP-ribosylation of Galphai and could be observed in S49-cyc- cells lacking Galphas indicating that, unlike the conventional agonist isoproterenol, these drugs induce ERK1/2 activation in a Gs/i-independent manner. In contrast, this activation was inhibited by a dominant negative mutant of beta-arrestin and was abolished in mouse embryonic fibroblasts lacking beta-arrestin 1 and 2. The role of beta-arrestin was further confirmed by showing that transfection of beta-arrestin 2 in these knockout cells restored ICI118551 promoted ERK1/2 activation. ICI118551 and propranolol also promoted beta-arrestin recruitment to the receptor. Taken together, these observations suggest that beta-arrestin recruitment is not an exclusive property of agonists, and that ligands classically classified as inverse agonists rely exclusively on beta-arrestin for their positive signaling activity. This phenomenon is not unique to beta2-adrenergic ligands because SR121463B, an inverse agonist on the V2 vasopressin receptor-stimulated adenylyl cyclase, recruited beta-arrestin and stimulated ERK1/2. These results point to a multistate model of receptor activation in which ligand-specific conformations are capable of differentially activating distinct signaling partners.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679574      PMCID: PMC208770          DOI: 10.1073/pnas.1936664100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists.

Authors:  C Watson; G Chen; P Irving; J Way; W J Chen; T Kenakin
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3.

Authors:  P H McDonald; C W Chow; W E Miller; S A Laporte; M E Field; F T Lin; R J Davis; R J Lefkowitz
Journal:  Science       Date:  2000-11-24       Impact factor: 47.728

3.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex.

Authors:  K A DeFea; Z D Vaughn; E M O'Bryan; D Nishijima; O Déry; N W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization.

Authors:  R H Oakley; S A Laporte; J A Holt; L S Barak; M G Caron
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

5.  The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor.

Authors:  S Maudsley; K L Pierce; A M Zamah; W E Miller; S Ahn; Y Daaka; R J Lefkowitz; L M Luttrell
Journal:  J Biol Chem       Date:  2000-03-31       Impact factor: 5.157

6.  beta 2-adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein rap1 and the serine/threonine kinase B-Raf.

Authors:  J M Schmitt; P J Stork
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

7.  Nitric oxide modulates beta(2)-adrenergic receptor palmitoylation and signaling.

Authors:  L Adam; M Bouvier; T L Jones
Journal:  J Biol Chem       Date:  1999-09-10       Impact factor: 5.157

8.  beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking.

Authors:  T A Kohout; F S Lin; S J Perry; D A Conner; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

9.  Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET).

Authors:  S Angers; A Salahpour; E Joly; S Hilairet; D Chelsky; M Dennis; M Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2.

Authors:  K A DeFea; J Zalevsky; M S Thoma; O Déry; R D Mullins; N W Bunnett
Journal:  J Cell Biol       Date:  2000-03-20       Impact factor: 10.539

View more
  184 in total

1.  Development and characterization of pepducins as Gs-biased allosteric agonists.

Authors:  Richard Carr; Yang Du; Julie Quoyer; Reynold A Panettieri; Jay M Janz; Michel Bouvier; Brian K Kobilka; Jeffrey L Benovic
Journal:  J Biol Chem       Date:  2014-11-13       Impact factor: 5.157

2.  V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.

Authors:  Kazuhiro Takahashi; Noriko Makita; Katsunori Manaka; Masataka Hisano; Yuko Akioka; Kenichiro Miura; Noriyuki Takubo; Atsuko Iida; Norishi Ueda; Makiko Hashimoto; Toshiro Fujita; Takashi Igarashi; Takashi Sekine; Taroh Iiri
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

3.  Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes.

Authors:  Sonia Terrillon; Michel Bouvier
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

4.  Nuclear β-adrenergic receptors modulate gene expression in adult rat heart.

Authors:  George Vaniotis; Danny Del Duca; Phan Trieu; Charles V Rohlicek; Terence E Hébert; Bruce G Allen
Journal:  Cell Signal       Date:  2010-08-21       Impact factor: 4.315

5.  Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements.

Authors:  Ralf Schröder; Nicole Janssen; Johannes Schmidt; Anna Kebig; Nicole Merten; Stephanie Hennen; Anke Müller; Stefanie Blättermann; Marion Mohr-Andrä; Sabine Zahn; Jörg Wenzel; Nicola J Smith; Jesús Gomeza; Christel Drewke; Graeme Milligan; Klaus Mohr; Evi Kostenis
Journal:  Nat Biotechnol       Date:  2010-08-15       Impact factor: 54.908

Review 6.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 7.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

8.  Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

9.  Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Mol Pharmacol       Date:  2017-09-01       Impact factor: 4.436

Review 10.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.